Johnson & Johnson

3Q Revenues: $17.8 billion (+4%)

3Q Earnings: $4.3 billion (+27%)

YTD Revenues: $53.8 billion (+3%)

YTD Earnings: $12.7 billion (-15%)

Comments: Worldwide Pharmaceutical sales were $8.4 billion in the quarter, up 9%. Domestic sales increased 12% and international sales increased 5%. REMICADE sales were $1.8 billion in the quarter, up 11%. STELARA sales were $814 million, up 33%. SIMPONI/SIMPONI ARIA sales were $481 million, up 27%. INVEGA SUSTENNA sales were $556 million, up 21%. OLYSIO /SOVRIAD Hep C sales were down 73% in the quarter to $21 million. IMBRUVICA sales were up 90% to $349 million and XARELTO sales were $529 million, up 15%. Operational results were impacted by acquisitions (Abbott Medical Optics for $4.3 billion), divestitures (Cordis) and drop in hepatitis C sales. Worldwide Consumer sales were $3.3 billion, down 2%. Worldwide Medical Devices sales were $6.2 billion, up 1%.